Site Activity
This page provides a monthly listing of publication activity on the Medical Policy Portal including Policy Notifications, New Policies, Updated Policies, Coding Updates, Reissued Policies, and Archived Policies. To view publication activity from prior months, select Past Site Activity.

Past Site Activity
 
                                                                                                        

Notifications
The following Independence Blue Cross Medicare Advantage policies have been posted prior to their effective date.
MA08.037d, Bortezomib (Bortezomib for Injection, Velcade®)
Notification: 06/08/2018 | Effective: 07/09/2018 | Posted: 06/08/2018
Type of policy change: Medical Necessity Criteria; Medical Coding; General Description, Guidelines, or Informational Update

MA11.058a, Otoplasty Otoplasty or Non-Surgical External Ear Molding
Notification: 06/12/2018 | Effective: 09/10/2018 | Posted: 06/12/2018
Type of policy change: Coverage and/or Reimbursement Position; Medical Coding; General Description, Guidelines, or Informational Update

MA07.004d, Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)
Notification: 06/13/2018 | Effective: 09/10/2018 | Posted: 06/13/2018
Type of policy change: Medical Necessity Criteria; Medical Coding; General Description, Guidelines, or Informational Update

MA05.053f, Implantable and External Infusion Pumps
Notification: 06/27/2018 | Effective: 07/30/2018 | Posted: 06/27/2018
Type of policy change: Coverage and/or Reimbursement Position; Medical Necessity Criteria

MA08.007k, Medicare Part B vs. Part D Crossover Drugs
Notification: 06/27/2018 | Effective: 07/30/2018 | Posted: 06/27/2018

MA09.020f, Radiation Therapy Services
Notification: 06/29/2018 (revised 07/26/2018) | Effective: 10/01/2018 | Posted: 06/29/2018
Type of policy change: Medical Coding; General Description, Guidelines, or Informational Update


Updated Policies
The following Medicare Advantage policies have been reviewed and updated to communicate current coverage and/or reimbursement positions, reporting requirements, and other procedures for doing business with Independence Blue Cross.
MA08.059d, Ipilimumab (Yervoy®)
Effective: 06/04/2018 | Posted: 06/04/2018
Type of policy change: Medical Necessity Criteria; General Description, Guidelines, or Informational Update

MA05.047c, Treatment of Obstructive Sleep Apnea (OSA) and Primary Snoring in Adults
Effective: 06/18/2018 | Posted: 06/18/2018
Type of policy change: Coverage and/or Reimbursement Position; Medical Coding; General Description, Guidelines, or Informational Update

MA07.024b, Medical and Surgical Treatment of Temporomandibular Joint Disorder
Effective: 06/25/2018 | Posted: 06/25/2018
Type of policy change: Coverage and/or Reimbursement Position


Reissue Policies
The following Medicare Advantage policies have been reviewed, and no substantive changes were made.
MA11.006b, Bronchial Thermoplasty
Reissue Effective: 06/06/2018 | Reissue Posted: 06/06/2018

MA10.005a, Day Rehabilitation
Reissue Effective: 06/06/2018 | Reissue Posted: 06/06/2018

MA07.005a, Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices
Reissue Effective: 06/06/2018 | Reissue Posted: 06/07/2018

MA07.052, Bioimpedance for the Detection of Lymphedema
Reissue Effective: 06/06/2018 | Reissue Posted: 06/07/2018

MA02.003a, Home Health Care Services
Reissue Effective: 06/06/2018 | Reissue Posted: 06/07/2018

MA01.004a, Continuous Local Delivery of Anesthesia to Operative Sites Using an Elastomeric Infusion Pump
Reissue Effective: 06/06/2018 | Reissue Posted: 06/07/2018

MA10.001, Pulmonary Rehabilitation Services
Reissue Effective: 06/06/2018 | Reissue Posted: 06/07/2018

MA08.006e, Siltuximab (Sylvant®)
Reissue Effective: 06/15/2018 | Reissue Posted: 06/15/2018

MA08.033a, Agalsidase beta (Fabrazyme®)
Reissue Effective: 06/15/2018 | Reissue Posted: 06/15/2018

MA08.078b, Sebelipase alfa (Kanuma®)
Reissue Effective: 06/15/2018 | Reissue Posted: 06/15/2018

MA08.036b, Alglucosidase alfa (e.g., Lumizyme®)
Notification: 12/22/2017 | Reissue Effective: 06/15/2018 | Reissue Posted: 06/15/2018

MA08.089a, Cerliponase alfa (Brineura™)
Reissue Effective: 06/15/2018 | Reissue Posted: 06/15/2018

MA08.015c, Alemtuzumab (Lemtrada™)
Reissue Effective: 06/15/2018 | Reissue Posted: 06/15/2018

MA02.001a, Hospice Care
Reissue Effective: 06/20/2018 | Reissue Posted: 06/20/2018

MA07.010a, Biofeedback Therapy
Reissue Effective: 06/202018 | Reissue Posted: 06/20/2018

MA05.008a, Negative Pressure Wound Therapy (NPWT) Systems
Reissue Effective: 06/20/2018 | Reissue Posted: 06/20/2018

MA11.079c, Evaluation and Treatment of Erectile Dysfunction (ED)
Reissue Effective: 06/20/2018 | Reissue Posted: 06/20/2018

MA11.043, Reimbursement for a Presbyopia- or Astigmatism-Correcting Intraocular Lens
Reissue Effective: 06/20/2018 | Reissue Posted: 06/20/2018

MA07.042, Complete Decongestive Therapy (CDT)
Reissue Effective: 06/20/2018 | Reissue Posted: 06/20/2018

MA07.013c, Electrical Stimulation and Electromagnetic Stimulation for the Treatment of Wounds
Reissue Effective: 06/20/2018 | Reissue Posted: 06/21/2018


Coding Update
The following Medicare Advantage policies have been reviewed and updated to add new and revised medical codes (e.g., ICD-9 and ICD-10 diagnosis codes; CPT® and HCPCS codes; revenue codes) and/or remove terminated medical codes.
MA08.094a, Voretigene Neparvovec-rzyl (Luxturna)
Effective: 07/01/2018 | Posted: 06/29/2018

MA08.004l, Coagulation Factors
Effective: 07/01/2018 | Posted: 06/29/2018


Archived Policies
Independence Blue Cross has determined that it is no longer necessary for the following Medicare Advantage policy to remain active.
MA08.051c, C1 Esterase Inhibitors: Cinryze®, Berinert®, and Ruconest®
Notification: 06/15/2018 | Archive Effective: 07/16/2018 | Posted: 06/15/2018










Connect with Us        


© 2017 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.